| pubmed-article:11896112 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11896112 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:11896112 | lifeskim:mentions | umls-concept:C1518932 | lld:lifeskim |
| pubmed-article:11896112 | lifeskim:mentions | umls-concept:C0085669 | lld:lifeskim |
| pubmed-article:11896112 | lifeskim:mentions | umls-concept:C0146224 | lld:lifeskim |
| pubmed-article:11896112 | lifeskim:mentions | umls-concept:C0205267 | lld:lifeskim |
| pubmed-article:11896112 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:11896112 | lifeskim:mentions | umls-concept:C0086960 | lld:lifeskim |
| pubmed-article:11896112 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:11896112 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:11896112 | pubmed:dateCreated | 2002-3-15 | lld:pubmed |
| pubmed-article:11896112 | pubmed:abstractText | To determine dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of a protracted, intermittent schedule of daily 30-minute infusions of topotecan (TPT) for up to 12 consecutive days, every 3 weeks, in children with refractory leukemia. | lld:pubmed |
| pubmed-article:11896112 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11896112 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11896112 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11896112 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11896112 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11896112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11896112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11896112 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11896112 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:11896112 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:11896112 | pubmed:author | pubmed-author:PrattCharlesC | lld:pubmed |
| pubmed-article:11896112 | pubmed:author | pubmed-author:BaruchelSylva... | lld:pubmed |
| pubmed-article:11896112 | pubmed:author | pubmed-author:SteuberC... | lld:pubmed |
| pubmed-article:11896112 | pubmed:author | pubmed-author:FurmanWayne... | lld:pubmed |
| pubmed-article:11896112 | pubmed:author | pubmed-author:StewartClinto... | lld:pubmed |
| pubmed-article:11896112 | pubmed:author | pubmed-author:KirsteinMarkM | lld:pubmed |
| pubmed-article:11896112 | pubmed:author | pubmed-author:KepnerJames... | lld:pubmed |
| pubmed-article:11896112 | pubmed:author | pubmed-author:BernsteinMark... | lld:pubmed |
| pubmed-article:11896112 | pubmed:author | pubmed-author:KungFaithF | lld:pubmed |
| pubmed-article:11896112 | pubmed:author | pubmed-author:ViettiTeresa... | lld:pubmed |
| pubmed-article:11896112 | pubmed:author | pubmed-author:BectonDavid... | lld:pubmed |
| pubmed-article:11896112 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11896112 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:11896112 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:11896112 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11896112 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11896112 | pubmed:pagination | 1617-24 | lld:pubmed |
| pubmed-article:11896112 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:11896112 | pubmed:meshHeading | pubmed-meshheading:11896112... | lld:pubmed |
| pubmed-article:11896112 | pubmed:meshHeading | pubmed-meshheading:11896112... | lld:pubmed |
| pubmed-article:11896112 | pubmed:meshHeading | pubmed-meshheading:11896112... | lld:pubmed |
| pubmed-article:11896112 | pubmed:meshHeading | pubmed-meshheading:11896112... | lld:pubmed |
| pubmed-article:11896112 | pubmed:meshHeading | pubmed-meshheading:11896112... | lld:pubmed |
| pubmed-article:11896112 | pubmed:meshHeading | pubmed-meshheading:11896112... | lld:pubmed |
| pubmed-article:11896112 | pubmed:meshHeading | pubmed-meshheading:11896112... | lld:pubmed |
| pubmed-article:11896112 | pubmed:meshHeading | pubmed-meshheading:11896112... | lld:pubmed |
| pubmed-article:11896112 | pubmed:meshHeading | pubmed-meshheading:11896112... | lld:pubmed |
| pubmed-article:11896112 | pubmed:meshHeading | pubmed-meshheading:11896112... | lld:pubmed |
| pubmed-article:11896112 | pubmed:meshHeading | pubmed-meshheading:11896112... | lld:pubmed |
| pubmed-article:11896112 | pubmed:meshHeading | pubmed-meshheading:11896112... | lld:pubmed |
| pubmed-article:11896112 | pubmed:meshHeading | pubmed-meshheading:11896112... | lld:pubmed |
| pubmed-article:11896112 | pubmed:meshHeading | pubmed-meshheading:11896112... | lld:pubmed |
| pubmed-article:11896112 | pubmed:meshHeading | pubmed-meshheading:11896112... | lld:pubmed |
| pubmed-article:11896112 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11896112 | pubmed:articleTitle | Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. | lld:pubmed |
| pubmed-article:11896112 | pubmed:affiliation | Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN, USA. wayne.furman@stjude.edu | lld:pubmed |
| pubmed-article:11896112 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11896112 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11896112 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:11896112 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11896112 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11896112 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11896112 | lld:pubmed |
